WMS 2019

This website is intended only for healthcare professionals outside the US, UK and Australia.

Specialities
Conferences
Digital Health
Services

Dermatology

Gastro immunology

Haematology

Neuroscience

Oncology

Ophthalmology

Respiratory

Rheumatology
Dermatology

Pemphigus Vulgaris

Gastro immunology

Crohn's disease & Ulcerative colitis

Haematology

Haemophilia Leukemia & Lymphoma

Neuroscience

Alzheimer's Disease Huntington's Disease Multiple sclerosis Neuromyelitis Optica Spectrum Disorder (NMOSD)

Oncology

Breast Cancer Genitourinary (GU) Cancer Lung Cancer

Ophthalmology

Geographic Atrophy

Respiratory

Cystic Fibrosis Idiopathic Pulmonary Fibrosis

Rheumatology

Giant Cell Arteritis Rheumatoid Arthritis

Floodlight

Clinical Trials ForPatients Investigator Initiated Studies Medical Information Request Pipeline Research Cancer Immunotherapy Website

Roche at WMS 2019

Posters

Oct 02, 2019 | Spinal Muscular Atrophy WMS 2019 Spinal Muscular Atrophy

FIREFISH Part 1: 16-month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with Type 1 spinal muscular atrophy (SMA)

Oct 02, 2019 | Spinal Muscular Atrophy WMS 2019 Spinal Muscular Atrophy

RAINBOWFISH: A study of risdiplam (RG7916) in newborns with pre-symptomatic spinal muscular atrophy (SMA)

Oct 02, 2019 | Spinal Muscular Atrophy WMS 2019 Spinal Muscular Atrophy

JEWELFISH: Safety and pharmacodynamic data in patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam (RG7916) that have previously been treated with nusinersen